Please login to the form below

Not currently logged in
Email:
Password:

darunavir-STR

This page shows the latest darunavir-STR news and features for those working in and with pharma, biotech and healthcare.

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

The STR provided ‘effective’and ‘durable’viral suppression. Janssen’s darunavir-based single tablet regimen (STR) Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) showed a positive outcome in the treatment of HIV

Latest news

  • Janssen wins European approval for Symtuza Janssen wins European approval for Symtuza

    The European Commission (EC) has approved Janssen’s Symtuza (darunavir-STR) to treat adults with human immunodeficiency virus type 1 (HIV-1). ... Dr Frank Wiegand, medical director, Janssen UK, said: “The decision by the European Commission to

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics